AldexBIO's first-generation ionizable lipids have also been granted patent protection in China.

AldexBIO provides a de-risked, high-performance ionizable lipid platform designed to solve the core IP and performance challenges in therapeutic delivery. Our mission is to provide strategic partners with a powerful engine to accelerate the development of next-generation genetic medicines. Our platform is built on four core pillars of value, creating a compelling, turnkey solution for integration into a leading pharma or CDMO organization: • Dominant & Defensible IP: We operate in a competition-free chemical space, secured by a multi-layered patent fortress that protects our catalysts, compositions, and therapeutic use. This ensures a clean Freedom-to-Operate (FTO) position for our partners. • Demonstrably Superior Performance: Our platform consistently delivers lipids that outperform industry benchmarks, with head-to-head data confirming a 3-4x potency improvement and a superior safety profile in repeat-dose toxicology studies. • A High-Performance Discovery Engine: Our combinatorial engine uses simple, readily available starting materials to provide access to a near-limitless library of novel structures. This platform combines unprecedented speed with the unique strategic capability of "Lipid Remastering" to secure and enhance existing assets. • A Clear Path to Commercialization: The entire synthesis is built on simple, scalable chemical transformations, providing high confidence for a seamless and cost-effective transition from the lab to GMP manufacturing. AldexBIO is actively seeking a strategic partner to deploy this powerful platform to capture the next wave of therapeutic innovation.

Founded 2024